Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

319.87
+4.411.40%
Pre-market: 324.004.13+1.29%04:47 EDT
Volume:317.11K
Turnover:101.70M
Market Cap:7.10B
PE:-17.80
High:327.59
Open:315.04
Low:314.57
Close:315.46
Loading ...

Loss-Making Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Expected To Breakeven In The Medium-Term

Simply Wall St.
·
09 Jul

Madrigal Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
21 Jun

Positive CHMP Opinion Boosts Madrigal Pharmaceuticals’ Prospects for Rezdiffra in EU Market

TIPRANKS
·
21 Jun

Sector Update: Health Care Stocks Rise Premarket Friday

MT Newswires Live
·
20 Jun

Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount

MT Newswires Live
·
20 Jun

Madrigal Pharmaceuticals receives positive CHMP opinion for resmetirom

TIPRANKS
·
20 Jun

Madrigal Receives Positive Chmp Opinion for Resmetirom (Rezdiffra™) for the Treatment of Mash With Moderate to Advanced Liver Fibrosis

THOMSON REUTERS
·
20 Jun

BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Reuters
·
20 Jun

EU medicines regulator grants conditional authorisation for Madrigal's liver disease drug

Reuters
·
20 Jun

Ema's Chmp: Recommended Granting Conditional Marketing Authorisation for Rezdiffra, for Treatment of Adults With Noncirrhotic Mash

THOMSON REUTERS
·
20 Jun

BRIEF-Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq listing rule

Reuters
·
18 Jun

Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial

Reuters
·
13 May

BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis

Reuters
·
10 May

Madrigal Pharmaceuticals Inc - Patients Achieved 6.7 Kpa Reduction in Liver Stiffness

THOMSON REUTERS
·
10 May

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (Resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients With Compensated Mash Cirrhosis

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals Inc - Rezdiffra Well-Tolerated With Low Discontinuation Rate

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals: 65% of Patients With Clinically Significant Portal Hypertension at Baseline Moved Into Lower Risk Categories by Year Two

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals Is Maintained at Buy by UBS

Dow Jones
·
03 May

Madrigal Pharmaceuticals Price Target Raised to $460.00/Share From $422.00 by B. Riley Securities

Dow Jones
·
03 May

Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
02 May